Bristol-myers Squibb Compnay

John S Sack

Alan J Korman

Haichun Huang

Mohan Srinivasan

Nils Lonberg

Guodong Chen

Maria N Jure-Kunkel

Aaron Paul Yamniuk

Richard Y Huang

Karla Ann Henning

Martin J Corbett

Bryan C Barnhart

Ming Lei

Liang Schweizer

Sandra V Hatcher

Emanuela Sega

Angela Goodenough

Joseph E Myers, Jr

Pingping Zhang

Mark E Salvati

Stanley Richard Krystek, Jr

Ricardo Attar

John S Tokarski

Roberto Weinmann

Chihuei Wang

Marco Gottardis

Joseph E Myers

Howard M Einspahr

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

Antibodies against CD73

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

The first crystal structure of the androgen receptor ligand binding domain has been determined to 2.0 angstrom resolution. Disclosed are the coordinates for the crystal structure, and methods for determining agonists, partial agonists, antagonists, partial antagonists and selective androgen receptors modulators (SARMs) of the androgen receptor.

Crystallographic structure of the androgen receptor ligand binding domain

Selective androgen receptor modulators (SARMs) having antagonist activity in hormone-dependent tumors while exhibiting no activity or agonist activity against other nontumor tissues containing the androgen receptor as well as methods for identifying, designing and using SARMs are provided.

Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator

Growing community of inventors

Lawrenceville, NJ, United States of America

John S Sack